FORM 4

## UNITED STATES SECURITIES AND FXCHANGE COMMISSION

Washington, D.C. 20549

3 1A1E3 3ECU	KH	3	ANL	ノヒス	ANGE	COM	M1122	NOI	١

OMB APPROVAL

3235-0287 OMB Number: Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  GOLDSTEIN JOSEPH L					RE	2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS, INC. [ REGN ]										5. Relationship of Reporting Person(s) to Issuer (Check all applicable)    Director 10% Owner Officer (give title Other (specify					
(Last) (First) (Middle) 777 OLD SAW MILL RIVER ROAD						3. Date of Earliest Transaction (Month/Day/Year) 01/02/2025										elow)			below)	респу	
(Street) TARRY		State)	10591 (Zip)			4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)  Form filed by One Reporting Person Form filed by More than One Reporting Person						
1. Title of Security (Instr. 3)  2. Trans. Date							3. Tra	Transaction Disposed Of (D) (Instr. 3, 4 Code (Instr. 5)				red (A) or str. 3, 4 an	) or 5. Amount			Form:	: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
Common Stock			01/02	2/2025		Coo	1	Ai	mount 166	(A) o (D)	Price	(In:	Transaction(s) (Instr. 3 and 4) 6,548			D					
		1	Table II -								•	,	or Ben ble sec		y Owr	ned			·		
Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	i. Fransaction Code (Instr. 3)				6. Date Exercisal Expiration Date (Month/Day/Year)			and	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Natur of Indired Beneficia Ownersh (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	able	Expir Date	ation	Title	Amount or Number of Shares							
Non- Qualified Stock Option (right to	\$719.37	01/02/2025			A		1,958		(2)		01/02	2/2035	Common Stock	1,958	\$0.	0	1,958		D		

## **Explanation of Responses:**

- 1. Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
- 2. On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.

/s/ Joseph L. Goldstein

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.